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ABSTRACT
Conclusions BMI-1 is an upstream repressor of tumor suppressor p16 and their inverse expression
patterns have been linked with patient survival in OPSCC. In this material only p16 remained a
relevant prognostic marker in OPSCC.
Objectives HNSCC tumors carry variable phenotypes and clinical outcomes depending on their
anatomical location. In OPSCC, expression of tumor suppressor p16 is used as a surrogate marker of
HPV infection and has prognostic value. There are no good prognostic biomarkers for HNSCC
tumors of other anatomical locations.
Aim To study the expression patterns of p16 and BMI-1 in not only oropharyngeal but also oral,
hypopharyngeal, and laryngeal squamous cell carcinomas and to clarify their putative connections
with clinical parameters, survival, and each other.
Method Hospital records on 130 patients (59 OPSCC, 18 OSCC, 20 HPSCC, and 33 LSCC) diagnosed
between 1997–2008 at the Helsinki University Hospital, Finland, were reviewed. BMI-1 and p16
expressions were studied by immunohistochemistry.
Results Sixty-eight per cent of OPSCC expressed p16 and expression correlated with lower age,
lower T- and higher N-category, and with improved OS and DFS. BMI-1 expression was most
prevalent in OPSCC and LSCC, but had no clinical correlations. No correlation between p16 and
BMI-1 expression was found.
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Introduction
The 5-year survival in head and neck squamous cell cancers
(HNSCC) varies according to tumor anatomical location and
stage, and even within clinically homologous tumors treatment
response can be unpredictable. Numerous studies have tried to
find biomarkers that would foresee tumor behavior and aid in
clinical decision-making. Currently, the most reliable bio-
markers in use are the presence of human papilloma virus
(HPV) and the expression of its surrogate marker p16 in
oropharyngeal squamous cell carcinoma (OPSCC) – HPV
being the only prognostic marker cited in the 2015 NCCN
guidelines [1–3]. For HNSCC of other anatomical localizations
there are still no good biomarkers in clinical use.
It is thought that the malignant transformation of HPV
positive OPSCC tumor is mainly caused by oncoproteins E6
and E7 [1,2]. The unspliced variant of E6 oncoprotein forms a
complex with an ubiquitin-protein ligase leading to subsequent
degradation of tumor suppressor p53 through its ubiquitina-
tion [1,2]. E7 oncoproteins inactivate another important
tumor suppressor Rb and its associated pocket proteins.
This inactivation leads to over-expression of active E2F
transcription factors resulting in increased cell proliferation
[1,2]. Due to a negative feedback loop, Rb inactivation in HPV
positive tumors leads to increased levels of p16 [1–3]. This is
why immunohistochemical staining of p16 protein expression
can be used as a biomarker for tumor infected with HPV virus
[3]. p16 is a tumor suppressor encoded by the INK4a/Arf
locus. p16 inhibits cyclin D1-cyclin dependent kinase complex
that acts through phosphorylation of tumor suppressor Rb [4].
After phosphorylation, Rb protein becomes inactive, which
enables the cell cycle to progress and tumor growth. As p16
inhibits the inactivation of Rb, high levels of p16 lead to cell
cycle arrest [1].
B-cell-specific Moloney murine leukemia virus integration
site 1 (BMI-1) is a transcription factor and epigenetic regulator,
essential in maintaining the transcriptionally repressed state of
many genes through methylation and acetylation of chromatin
and histones [5]. BMI-1 regulates genes involved in the cell
cycle and cell differentiation and can, therefore, act as a potent
oncogene [6,7]. BMI-1’s effect is mediated partly through
repression of the INK4a/ARF, a locus encoding p16 [4]. Up-
regulation of BMI-1 leads to repression of p16. This causes
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tumor suppressor pRb inactivation through phosphorylation,
leading to cell cycle progression. Over-expression of BMI-1 has
been shown in multiple malignant tumors, including naso-
pharyngeal and oral carcinomas [6,8]. In HNSCC, BMI-1
expression is linked with promotion of both tumor formation
and invasion, as well as tumors metastatic capacity and
increased resistance to ionizing radiation [6,7,9,10].
In OPSCC, p16 has been associated with better survival [3].
The presence and significance of this association in other types
of HNSCC remains unclear [11,12]. BMI-1 expression has
been linked with both better and worse survival of cancer
patients. In OPSCC and laryngeal squamous cell carcinoma an
inverse relation between p16 and BMI-1 expression has been
reported to affect tumor stage and patient survival [4,13]. In
this study we investigated the expression of p16 and BMI-1 in
OPSCC, oral (OSCC), hypopharyngeal (HPSCC), and laryn-
geal (LSCC) squamous cell carcinoma. Our aim was to clarify
the possible associations between expression levels of these two
proteins and to assess their use as putative prognostic factors of
survival in different types of HNSCC.
Patients and methods
Retrospective clinicopathological data of 130 patients diagnosed
with histologically verified HNSCC between 1997–2008 at the
Helsinki University Hospital, Helsinki, Finland were reviewed.
There were 59 OPSCC patients, 33 LSCC, 20 HPSCC, and 18
OSCC. Patients with nasopharyngeal tumors were excluded, as
were patients with unknown primaries, and patients with less
than 2 years follow-up time. All patients were treated with
curative intent. Patient characteristics are shown in Table 1.
For immunohistochemical (IHC) stainings we used 130
formalin-fixed and paraffin-embedded tumor samples
obtained from the archives of Department of Pathology,
Helsinki University Hospital. The samples were cut into
4–5mm-thick sections, deparaffinized in xylene, and rehy-
drated through a graded alcohol series. For antigen retrieval,
slides were treated in a PT module (LabVision,
Cambridgeshire, UK) with Tris–HCl buffer (8.5) (for BMI-1)
or Tris-EDTA (9.0) for p16. BMI-1 IHC was performed in
Autostainer 480 (LabVision). Slides were treated with 0.3%
Dako REAL peroxidase-blocking solution to block endogenous
peroxidase activity followed by primary antibody incubation
with mouse monoclonal BMI-1 (ab 14389) (Abcam,
Cambridge, UK, 1:750) or ready-to-use mouse anti-human
p16 INK4a antibody clone 9511 CINtecTM histology kit
(MTMLabs, Heidelberg, Germany), followed by a 30-min
incubation with Dako REAL EnVision/HRP detection system,
rabbit/mouse (ENV) reagent. Ten minutes of Dako REAL
DAB+Chromogen (Dako) finally visualized reaction products.
PBS-0.04%-Tween20 washing was accomplished between each
step. Slides were counterstained with Meyer’s hematoxylin and
mounted in mounting medium (Aquamount, BDH, Poole,
UK). The BMI-1 antibody has previously been used in other
published studies from our department [14] and p16 is in
routine diagnostic use at the Department of Pathology.
IHCs were evaluated by two independent pathologists (IL
and JH), blinded to clinical data. They approximated the
percentage of positive cells within the tumor tissue. If 70% or
more of the tumor cells had nuclear and cytoplasmic staining
of p16, the expression was classified as positive (Figure 1).
BMI-1 staining was originally classified into six categories:
negative, extremely low (1–5% of tumor nuclei stained), very
low (6–30%), low (31–50%), moderate (51–80%), and high
(480%), but because of the small patient numbers in each
category, the groups were merged according to Hayry et al.
[14] into negative, low (1–50%), and high expression ( 51%,
Figure 1).
Statistical analysis was performed with IBM SPSS statistics
version 22. Anatomical sub-groups were analyzed separately.
Contingency variables were analyzed with Chi-square test or
Fischer’s exact test, means compared with Student’s t-test and
correlations with bivariate Pearson’s score. For survival
calculations we used Kaplan–Meier log-rank test and Cox
regression analysis where patient’s gender, age, stage, and
molecular markers were included. A p value of 0.05 was
considered statistically significant.
Results
Patients
The vast majority of the patients were men (79%), the
percentage being extremely high in HPSCC (90%) and LSCC
(91%). The mean age ranged from 56–61 years, being lowest in
patients with OPSCC and OSCC. More specific patient
characteristics and treatment modalities are described in
Table 1.
BMI-1 expression
The intensity of BMI-1 expression varied from negative to
high. Only nuclear expression pattern was regarded as positive.
In OSCC and HPSCC, most samples were BMI-1 negative,
whereas in LSCC 39%, and in OPSCC 58% of the samples
expressed nuclear BMI-1 but the differences were insignificant.
Only 10 of the 130 tumors showed high levels of BMI-1
expression (Table 1).
Table 1. Patient characteristics of 130 HNSCC patients.
OSCC
n¼ 18 (%)
OPSCC
n¼ 59 (%)
HPSCC
n¼ 20 (%)
LSCC
n¼ 33 (%)
Sex Men
Women
12 (67)
6 (33)
40 (68)
19 (32)
18 (90)
2 (10)
30 (91)
3 (9)
Mean age (range) 57 (26–79) 56 (29–73) 58 (31–81) 61 (40–84)
T category 1–2
3–4
11 (61)
7 (39)
40 (68)
29 (32)
4 (20)
15 (75)
13 (40)
20 (60)
N category 0–1
2–3
15 (84)
3 (16)
25 (42)
34 (58)
7 (35)
13(65)
28 (85)
4 (12)
Stage I–II
III–IV
9 (50)
9 (50)
8 (14)
51 (86)
0 (0)
20 (100)
11 (33)
22 (66)
Treatment Surgery
RT
CRT
Combined
8 (44)
0 (0)
0 (0)
10 (56)
1 (2)
0 (0)
5 (9)
53 (90)
0 (0)
0 (0)
14 (70)
6 (30)
6 (18)
3 (9)
7 (21)
17 (52)
BMI-1 Negative
Positive
Low
High
14 (78)
4 (22)
3 (17)
1 (5)
25 (42)
34 (58)
28 (48)
6 (10)
14 (70)
6 (30)
3 (15)
3 (15)
20 (61)
13 (39)
13 (39)
0 (0)
p16 Negative
Positive
17 (94)
1 (6)
19 (32)
40 (68)
16 (80)
4 (20)
32 (97)
1 (3)
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BMI-1’s correlations with clinical parameters
BMI-1 expression had no correlation with clinical parameters
including mean age, tumor size, nodal status, or stage in any
anatomical sub-groups.
p16 expression
When present, p16 expression was intense and uniform.
Positive immunostaining was most common in OPSCC (68%),
whereas in OSCC, HPSCC, and LSCC it was sparse (6%, 20%,
and 3%, respectively).
p16’s correlations with clinical parameters
In OPSCC, patients with p16 positive tumors were on average
younger than those with p16 negative tumors (54 vs 60 years,
p¼ 0.007). The same tendency was also seen in HPSCC,
although this finding lacked statistical significance (53 vs 60
years, p¼ 0.31). In OPSCC, p16 positivity was associated with
lower T category (p¼ 0.004) and higher N category (p50.001),
an association not seen in other groups. Statistical analysis was
not possible for OSCC and LSCC due to the small number of
patients (Table 1).
Survival
In OPSCC, positive p16 expression was linked with markedly
improved overall survival (OS, HR¼ 0.27, 95% CI¼ 0.07–1.00,
p¼ 0.05) and disease-free survival (DFS, HR¼ 0.27, 95%
CI¼ 0.09–0.83, p¼ 0.02, Figure 2), and this result remained
significant in multivariate analysis. A slight tendency towards
improved survival in BMI-1 negative OPSCC patients could be
seen, but this was statistically non-significant. When expres-
sion of BMI-1 and p16 were combined in survival analysis, it
was clear that the effect of p16 outweighed that of BMI-1
(Figure 3).
In OSCC, BMI-1 expression, which was positive in only
four patients, seemed to be associated with decreased
survival in DFS (p50.001, Figure 4), and the result was
confirmed in multivariate survival (HR¼ 5.03 95%
CI¼ 1.20–20.91, p¼ 0.03). In HPSCC or LSCC no statistic-
ally significant effects of p16 or BMI-1 expression on
survival were seen.
BMI-1 and p16 correlations
We found no significant correlations between p16 and BMI-1
expression in any anatomical locations.
Figure 1. Immunohistochemical stainings of BMI-1 (A¼ negative, B¼ low staining, 1–50%, and C¼ high staining,  51%), and p16 (D¼ negative, and
E¼ positive,  70% of cells stained).
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Discussion
BMI-1 is a member of a family of transcriptional repressors
[15] and a known upstream modulator of p16 [16]. BMI-1’s
effect on p16 expression is of interest as p16 is widely in
clinical use as a surrogate marker of HPV infection in OPSCC
[3]. Elevated levels of BMI-1 have been reported in several
cancers and its over-expression has been linked with cancer
therapy failure. However, in tongue cancer, lack of expression
has been shown to be associated with recurrence [14]. This
contradiction could be explained by the fact that, in addition to
its repressive effect on tumor suppressor p16, BMI-1 acts also
via numerous other pathways independent of p16. It has also
been suggested that BMI-1 alone should not be sufficient for
tumor progression [8,16].
Squamous cell carcinomas of the head and neck area are a
heterogeneous group of tumors with different phenotypes and
clinical outcomes. Several oncogenes/-proteins and tumor
suppressors have been studied as they are thought to form
the basis of biological tumor behavior, and their different
expression levels might serve as predictive or prognostic
factors. In this study, we investigated the expression levels of
both p16 and BMI-1 in HNSCC of different anatomical
locations, in order to study their co-expression’s possible effect,
as well as their associations with clinical parameters, and
survival. In OPSCC, p16 expression was associated with better
OS and DFS, and p16 positivity was linked with younger age,
low T and high N categories – as was expected [17]. In other
HNSCC tumors, p16 expression was low (OSCC¼ 6%,
HPSCC¼ 20%, LSCC¼ 3%) and had no clear correlation
with clinical parameters or survival. This finding was in good
concordance with earlier results reporting up to 20% of non-
OPSCC patients to have p16 positive tumors [11,18].
BMI-1 is expressed in the cells of healthy oral mucosa and
also in tumor cells of various HNSCC [4,6–9,13,14]. Previously
both nuclear and cytoplasmic BMI-1 expressions have been
scored [4,7,13]. In our study, we scored the samples only for
nuclear staining, and used a cut-off of 50% for positive
staining – a system previously used in our institution [14]. The
cut-off points in other studies range from dichotomic positive-
vs-negative to 50% [6,9,14]. In this cohort the expression of
BMI-1 was more prevalent in OPSCC than in OSCC and
HPSCC. The expression in LSCC (39%) was in line with earlier
reports of 44–50% [7,13]. BMI-1 expression had no significant
correlation with clinical parameters. Based on positive BMI-1
staining of four patients with OSCC, we found an association
between the absence of BMI-1 expression and improved
survival in OSCC. A similar, statistically non-significant trend
Figure 4. Disease-free survival curve of BMI-1 expression in oral carcinoma
patients (n¼ 18), p50.001.
Figure 2. Kaplan–Meier survival curve of p16 expression in oropharyngeal
tumors, p¼ 0.018.
Figure 3. When combining p16 and BMI-1 expression in oropharyngeal tumors,
p16 expression seemed to have a greater impact on survival (p¼ 0.11).
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was also seen in OPSCC. These findings are in line with earlier
reports on OPSCC, LSCC and nasopharyngeal carcinoma
[4,6,7,13], but reciprocal when compared with the results of
Hayry et al. [14] on 73 patients with T1–T2N0 tongue cancers.
It is clear that further studies on larger patient cohorts are
needed before this finding can be further discussed.
As BMI-1 should repress p16 expression via the INK4a
locus [19], it is interesting to investigate the possible linkage
between their expression levels. Huber et al. [4] were able to
show that negative p16 expression, together with high
cytoplasmic BMI-1 expression, is associated with poor survival
in OPSCC. In LSCC nuclear co-expression, has been linked
with a higher risk for lymph node metastasis [13]. In our
limited material, we were not able to show a correlation
between p16 and BMI-1 expression. It is possible that p16 was
regulated through another pathway than that by BMI-1.
Whether this could be explained for example by the presence
of HPV remains unclear, as HPV status of the tumors was not
investigated in our patients.
We conclude that our finding of p16 expressions correlation
to younger age, small primary tumor with early regional spread
and to better overall and disease-free survival in patients with
OPSCC, is convergent with current literature [1,17,18]. BMI-1
positivity was most common in patients with OPSCC and had
no clear correlation with clinical parameters. A trend towards
better survival in BMI-1 negative patients was seen in OPSCC
and OSCC. Although BMI-1 is known to be an upstream
repressor of p16 and the expression levels of these two markers
have previously been linked with each other this phenomenon
was not seen in the present material. Whether this will be
explained by an alternative, p16-regulating pathway, is warrant
for further studies.
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